Aesthetic pharmaceutical company Galderma will release its liquid neuromodulator RelabotulinumtoxinA (Relfydess) in the UK this month.
Galderma explains Relfydess is designed to deliver fast and sustained results for glabellar and lateral canthal lines, and the liquid neuromodulator is optimised for simple volumetric dosing to increase ease-of-use and help ensure consistent dose/volume. Relfydess was launched in European markets in December, and Galderma has confirmed the neuromodulator will be available from May 2025 in the UK.
René Wipperich, general manager of Galderma UK & Ireland, commented, “Our commitment to innovation in biologics has positioned us uniquely as the only company offering a comprehensive portfolio of three distinct neuromodulators. By leveraging our leadership in the UK through cutting-edge scientific research, the launch of Relfydess proves our dedication to delivering advanced solutions that address the needs of both patients and healthcare professionals.”
